GlassScriptPhysician profile
Maurice F Mccarthy
NPI 1346219870
$9,178.27
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,344 · 2020: $961 · 2021: $1,495 · 2022: $1,796 · 2023: $1,555 · 2024: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,263 · Consulting Fee: $220 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,262.51 |
| Consulting Fee | $220.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,539.98 | 2019-2024 | Prolia, Evenity, Enbrel |
| Janssen Biotech, INC. | $1,340.75 | 2020-2024 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $988.33 | 2019-2024 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $906.13 | 2019-2024 | |
| Pfizer INC. | $822.46 | 2019-2024 | |
| Ucb, INC. | $785.14 | 2019-2024 | Cimzia |
| Abbvie INC. | $727.37 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $469.58 | 2021-2024 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $288.01 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $240.53 | 2021 | |
| Genentech USA, INC. | $198.21 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $157.72 | 2019-2020 | |
| Novo Nordisk INC | $121.81 | 2020-2022 | |
| Genzyme Corporation | $110.99 | 2019-2023 | |
| Lilly USA, LLC | $102.82 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $101.38 | 2019-2021 | |
| Abbott Laboratories | $47.90 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $36.35 | 2021-2022 | |
| Horizon Therapeutics Plc | $33.08 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.59 | 2023 | Cyltezo |
| Biohaven Pharmaceuticals, INC. | $27.01 | 2021 | |
| Esperion Therapeutics, INC. | $24.84 | 2021 | |
| Ferring Pharmaceuticals INC. | $24.77 | 2019 | |
| Medexus Pharma, INC. | $24.15 | 2019 | |
| Sobi, INC | $16.92 | 2019 | |
| Eisai INC. | $14.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurice Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.